While the media covers the Grassley stains and Stupak remarks oozing from Congress, Ray Woosley and the C-Path Institute with strong backing from Janet Woodcock at the FDA are remaking the drug development process, transforming it from a hit or miss method to a pathway for personalized medicine. Today C-Path announced a trans-atlantic agreement to use the same drug safety biomarker at the FDA and the EMEA, a historic first. And let's not forget that industry is collaborating, much to the consternation of DeLauro,Goozner, Mahar, Brownlee and pharmalot. Progress towards safer, more effective medicines using more reliable measures. Oh, the humanity.
Read more here
Read more here
